GM2-Activator Protein: A New Biomarker for Lung Cancer

Potprommanee, Laddawan; Ma, Haou-Tzong; Shank, Lalida; Juan, Yi-Hsiu; Liao, Wei-Hao; Chen, Shui‐Tein; Yu, Chong‐Jen

doi:10.1097/jto.0000000000000357

Cited by 22 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GM2A protein was reported to be a potential biomarker for lung cancer in an article by Potprommanee et al. and they found >5‐fold increase in the expression of GM2A in both urine and serum samples . Our study also showed the increased expression of GM2A in the urine samples of HE breast cancer patients suggests that GM2A may be a cancer‐specific urinary secreted protein.…”

Section: Discussionsupporting

confidence: 76%

See 1 more Smart Citation

Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics

et al. 2016

View full text Add to dashboard Cite

Globally, breast cancer is the second most common cancer among women. Although biomarker discoveries through various proteomic approaches of tissue and serum samples have been studied in breast cancer, urinary proteome alterations in breast cancer are least studied. Urine being a noninvasive biofluid and a significant source of proteins, it has the potential in early diagnosis of breast cancer. This study used complementary quantitative gel-based and gel-free proteomic approaches to find a panel of urinary protein markers that could discriminate HER2 enriched (HE) subtype breast cancer from the healthy controls. A total of 183 differentially expressed proteins were identified using three complementary approaches, namely 2D-DIGE, iTRAQ, and sequential window acquisition of all theoretical mass spectra. The differentially expressed proteins were subjected to various bioinformatics analyses for deciphering the biological context of these proteins using protein analysis through evolutionary relationships, database for annotation, visualization and integrated discovery, and STRING. Multivariate statistical analysis was undertaken to identify the set of most significant proteins, which could discriminate HE breast cancer from healthy controls. Immunoblotting and MRM-based validation in a separate cohort testified a panel of 21 proteins such as zinc-alpha2-glycoprotein, A2GL, retinol-binding protein 4, annexin A1, SAP3, SRC8, gelsolin, kininogen 1, CO9, clusterin, ceruloplasmin, and α1-antitrypsin could be a panel of candidate markers that could discriminate HE breast cancer from healthy controls.

show abstract

Section: Discussionsupporting

confidence: 76%

“…Potprommanee et al. have reported that human urinary GM2 activator protein is a potential biomarker for lung cancer . Morrissey et al.…”

Section: Introductionmentioning

confidence: 99%

Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Genetic and proteomics-based biomarkers are two major types of biomarkers, which can be identified through tumor cells, urine, sputum, blood, or other body fluids [ 3 ]. Table 3 demonstrates numerous lung cancer markers [ 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 ].…”

Section: Biomarkers For Lung Cancer Detectionmentioning

confidence: 99%

Screening and Biosensor-Based Approaches for Lung Cancer Detection

Wang

2017

Sensors

View full text Add to dashboard Cite

Early diagnosis of lung cancer helps to reduce the cancer death rate significantly. Over the years, investigators worldwide have extensively investigated many screening modalities for lung cancer detection, including computerized tomography, chest X-ray, positron emission tomography, sputum cytology, magnetic resonance imaging and biopsy. However, these techniques are not suitable for patients with other pathologies. Developing a rapid and sensitive technique for early diagnosis of lung cancer is urgently needed. Biosensor-based techniques have been recently recommended as a rapid and cost-effective tool for early diagnosis of lung tumor markers. This paper reviews the recent development in screening and biosensor-based techniques for early lung cancer detection.

show abstract

“…In our study, the five-year overall survival rate is over 40% for NSCLC patients 22 23 24 25 , as most cases of patients who require surgery are diagnosed at a early clinical stage (I and II). However, we report a different follow-up period using survival curves as in Fig.…”

Section: Discussionmentioning

confidence: 67%

High expression of SOX30 is associated with favorable survival in human lung adenocarcinoma

Han

Liu

Xiao

et al. 2015

Sci Rep

View full text Add to dashboard Cite

In our previous study, we had identified SOX30 as a novel tumor suppressor that acts through direct regulation of p53 transcription in human lung cancer. Here, we sought to determine the clinical relevance of SOX30 expression in a series of surgically-resected non-small cell lung cancer (NSCLC) patients. Analysis of SOX30 expression and clinico-pathologic features reveal a significant correlation of SOX30 expression with histological type (n = 220, P = 0.008) and clinical stage (n = 220, P = 0.024). Kaplan-Meier analysis indicates an association of high SOX30 expression with better prognosis in NSCLC patients (n = 220, P = 0.007). Via multivariate Cox-regression analysis, SOX30 expression is revealed to be an independent prognostic factor for overall survival (OS) of NSCLC patients (n = 220, P = 0.014, hazard ratio (HR) = 0.816). In particular, SOX30 is a favorable and independent prognostic factor in one main subtype of NSCLC, lung adenocarcinoma (ADC) patients (n = 150, P = 0.000, HR = 0.405), but not in another main subtype of NSCLC, squamous cell carcinoma patients. Furthermore, high expression of SOX30 represents a favorable and independent factor for the prognosis of ADC patients at clinical stage II (P = 0.013), with positive lymph node (P = 0.003), at histological grade 2 (P = 0.000) or grade 3 (P = 0.025). In summary, SOX30 expression represents an important prognostic factor for survival time in ADC patients.

show abstract

GM2-Activator Protein: A New Biomarker for Lung Cancer

Abstract: Our study demonstrates that GM2AP might serve as potential diagnostic and prognostic biomarkers in patients with lung cancer.

Cited by 22 publications

References 33 publications

Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics

Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics

Screening and Biosensor-Based Approaches for Lung Cancer Detection

High expression of SOX30 is associated with favorable survival in human lung adenocarcinoma

Contact Info

Product

Resources

About